InterCure: True International Cannabis Play
- InterCure offers a pure play on the European cannabis market with a focus on Israel.
- The company went public via a SPAC in April and now trades below the PIPE price at only $8.
- The stock is cheap at only 2x EV/'22 sales targets.
- This idea was discussed in more depth with members of my private investing community, Out Fox The Street. Learn More »
Update - July 25
The Israeli cannabis company could uplift to the Nasdaq as soon as this week. Investors should watch for a catalyst when this occurs with the stock only trading at $6.25 here after hitting a high of nearly $10.
Comments